Tricyclic inhibitors of poly(ADP-ribose) polymerases
US6495541B1 · kind B1 · utility
31Cited by
17References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2000 |
| Grant date | Dec 17, 2002 |
| Priority date | — |
| Expiry date | Jan 10, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapuetics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and nuerodegenerative disease. As cancer therapuetics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.